A Phase 1/2 interventional study of Dronabinol in Obstructive Sleep Apnea, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by VA Office of Research and Development · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development — 7 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · VA Office of Research and Development.
Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 24th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →7 of the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 40–65
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 30–60
VA Office of Research and Development · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: Up to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 92 across the 22 interventional studies, 3,351 across the 2 observational. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
7 of the studies in Sleep Apnea, Obstructive by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02703207VA Office of Research and DevelopmentNeurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD | 2026-12-31 |
| NCT06291870VA Office of Research and DevelopmentPredictors of Post-COVID-19 Clinical and Cognitive Consequences | 2026-12-31 |
| NCT05558501VA Office of Research and DevelopmentIntermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities | 2026-12-31 |
| NCT06477952VA Office of Research and DevelopmentDRonabinol Treatment of OSA | 2027-03-31 |
| NCT05156112VA Office of Research and DevelopmentOSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.
This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.
The criteria were revised on the registry on Nov 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. AHI 15-50 per hour on pre-treatment polysomnography
Exclusion Criteria:
Comorbid medical and psychiatric disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label Dronabinol treatment for two weeks.
Drug: Dronabinol
Open label Dronabinol treatment for two weeks.
Also known as: Marinol
Apnea Hypopnea Index (AHI)
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Time frame: 2 weeks
T<90
The change in time below 90% oxygen saturation (T\<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Time frame: 2 weeks
Psychomotor Vigilance Test (PVT)
The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol.
Time frame: 2 weeks
24-hour Mean Arterial Blood Pressure (BP)
The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording.
Time frame: 2 weeks
Sleep Efficiency
The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Time frame: 2 weeks
Rapid Eye Movement (REM) Sleep
The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Time frame: 2 weeks
Slow Wave Sleep
The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Time frame: 2 weeks
Treatment Satisfaction Questionnaire for Medication (TSQM)
Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction.
Time frame: 2 weeks
Epworth Sleepiness Scale (ESS)
The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness.
Time frame: 2 weeks
Functional Outcomes of Sleep Questionnaire (FOSQ)
The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status.
Time frame: 2 weeks
Pittsburgh Sleep Quality Index (PSQI)
The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality.
Time frame: 2 weeks
Insomnia Severity Index (ISI)
The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance.
Time frame: 2 weeks
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.
Time frame: 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol
VA Office of Research and Development →